Memorial Sisli Hospital
Die Gesamtkosten für die Behandlung von Neuroblastom in der Türkei variieren je nach Behandlungsplan. Eine Konsultation mit einem pädiatrischen Onkologen oder einem pädiatrischen Chirurgen kostet jeweils 151 €. Das Chemotherapie-Regime, bestehend aus sechs Kursen, kostet 51.200 €, und die chirurgische Entfernung des Tumors kostet 13.200 €. Zusätzlich werden 20 Sitzungen der Strahlentherapie auf 4.700 € geschätzt, und eine autologe Stammzelltransplantation kostet 30.700 €. Der Behandlungsplan wird nach einer umfassenden Bewertung des Zustands des Patienten durch medizinische Fachkräfte individuell angepasst.
| Türkei | Österreich | Spanien | |
| Komplexe Behandlung von Neuroblastom | von $28,000 | von $180,000 | von $70,000 |
Prof. Ceyhun Bozkurt ist Spezialist für pädiatrische Onkologie mit einer fortgeschrittenen Ausbildung in Neuroblastom-Behandlung am Dana-Farber Cancer Institute der Harvard University.
Spezialisiert auf zielgerichtete Therapien und Immuntherapie bei Neuroblastomen im Medical Park Antalya. Kombiniert fortschrittliche Genforschung mit patientenzentrierter Versorgung.
Prof. Yıldırım hat über 80 onkologische Werke veröffentlicht und ist Mitautorin eines Handbuchs für fortgeschrittene Krebstherapie. Sie ist Expertin für Immuntherapie und zielgerichtete Therapien.
Priv.-Doz. Dr. Babacan ist auf pädiatrische Hämatologie und Onkologie spezialisiert und verfügt über 13 Jahre Erfahrung mit Knochenmarktransplantationen bei Krebserkrankungen im Kindesalter.
Reputable Turkish hospitals for neuroblastoma include JCI-accredited centers like Anadolu Medical Center and Memorial Sisli Hospital. These facilities offer advanced immunotherapy and bone marrow transplants. Specialist teams use MIBG-scintigraphy and genetic research to stage high-risk pediatric cases for personalized treatment plans.
Bookimed Expert Insight: Anadolu Medical Center stands out because of its formal affiliation with Johns Hopkins Hospital. This ensures international standards for complex procedures. Our data shows it treats 65,000 patients annually. For neuroblastoma, this high volume is vital. It means the surgical and oncology teams handle rare cases frequently. This leads to better outcomes in staging and tumor resection.
Patient Consensus: Parents find quick diagnostic staging a major relief during the initial stressful weeks. They recommend choosing large centers with dedicated pediatric ICUs and in-house translators to manage long-term treatment logistics.
Turkish pediatric centers report a 5-year survival rate around 68% for high-risk neuroblastoma. Lower-risk cases achieve survival rates up to 98% following international protocols. Specialized clinics utilize autologous stem cell transplants and CAR NK cell therapy to improve outcomes for children with advanced-stage disease.
Bookimed Expert Insight: Quality signals for pediatric oncology in Turkey often correlate with high patient volumes and specialized certifications. For example, Medipol Mega University Hospital serves over 1,000,000 patients annually and was ranked specifically as the best clinic for pediatric cancer by Bookimed patients. Choosing a center with these specific volume-based credentials ensures access to experienced teams like those under Dr. Ceyhun Bozkurt, who trained at Harvard and Cincinnati Children’s.
Patient Consensus: Parents note that staging and diagnostic tests are performed very quickly in Istanbul. They emphasize that working with a high-volume team is essential for managing the uncertainty of a high-risk diagnosis.
Turkey offers advanced immunotherapy for high-risk neuroblastoma at specialized oncology centers. Treatment protocols often include CAR T-cell therapy and monoclonal antibodies. JCI-accredited hospitals in Istanbul provide these therapies alongside pediatric bone marrow transplants. Patients access these treatments through multidisciplinary teams of pediatric oncologists and surgeons.
Bookimed Expert Insight: Clinical data shows a concentration of neuroblastoma expertise in Istanbul. Prof. Dr. Ceyhun Bozkurt has published over 40 peer-reviewed studies on neuroblastoma. Centers like Medipol Mega serve over 1,000,000 patients annually. This high volume allows these facilities to maintain steady supplies of biological drugs. Choosing these large university-affiliated hospitals ensures access to the latest cell therapies.
Patient Consensus: Parents clarify that confirming anti-GD2 antibody availability is essential before starting the maintenance phase. Patients note that specialized centers in Istanbul provide fast staging and simple explanations of risk categories.
Neuroblastoma treatment in Turkey follows a multidisciplinary journey spanning 12 to 15 months. It integrates molecular diagnostics with intensive therapies like autologous stem cell transplants. Turkish centers utilize JCI-accredited protocols to manage high-risk cases. Treatment includes induction chemotherapy, surgical resection, and advanced immunotherapy.
Bookimed Expert Insight: Turkish oncology centers often lead in volume, with Medipol Mega treating 1,200 patients daily. Our data shows a pattern where top specialists like Prof. Dr. Ceyhun Bozkurt combine stem cell expertise with neuroblastoma care. This double specialization is vital. It ensures the transition from induction chemo to transplant is seamless within the same facility.
Patient Consensus: Parents note that staging and scans happen very quickly in Istanbul. This speed provides relief during a high-stress diagnosis period. They appreciate having dedicated translators who stay with them throughout the entire medical journey.
Turkish hospitals provide extensive international support services through dedicated departments. Facilities like Anadolu Medical Center and Memorial Health Group offer multilingual translation and logistics assistance. These services ensure seamless medical coordination for oncology patients traveling from over 160 countries for complex care.
Bookimed Expert Insight: Anadolu Medical Center maintains a unique advantage through its Johns Hopkins affiliation. This partnership ensures that international administrative protocols match American standards. Our data shows this consistency is vital for neuroblastoma cases requiring complex MIBG-scintigraphy and multidisciplinary pediatric oncology coordination.
Patient Consensus: Patients note that having a fixed translator and on-site currency exchange makes arriving in Istanbul much easier. They appreciate when clinics explain complex risk categories in simple terms during the staging process.